The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
August 19th 2025
The complete response letter (CRL) stated that vatiquinone's new drug application (NDA) did not provide substantial evidence of efficacy and would need to be evaluated in a new trial.
FDA Expands Indication of ALL Treatment for Patients with Increased Relapse Risk
March 30th 2018Officials with the FDA have expanded the approval of Amgen's blinatumomab (Blincyto) to include the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but still have minimal residual disease.
Read More